STAT6 gain-of-function disease: p.D519N is a new disease-causing variant that responds well to dupilumab treatment
Journal of Allergy and Clinical Immunology: Global · 2025-08 · 4 (3) · 100494
DOI: 10.1016/j.jacig.2025.100494 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Allergy and Clinical Immunology: Global, 2025-08. Verfasst von Simran Samra und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, British Columbia Children's Hospital, The University of British Columbia, Vancouver, British Columbia, Canada. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Genome British Columbia, University of British Columbia, Canada Research Chairs.
Abstract (Originalsprache)
This case report presents a new genetic variant that causes STAT6 gain-of-function disease in 2 patients, expands the clinical phenotype of STAT6 gain-of-function disease, and describes its authors' success in using therapeutics to manage this rare disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, British Columbia Children's Hospital, The University of British Columbia, Vancouver, British Columbia, Canada.
- Experimental Medicine Program, Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada.
- Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.
- Kids Cancer Centre, Sydney Children's Hospital, Sydney, Australia.
- Pharming Healthcare, Inc, Warren, NJ.
Förderung
- Genome British Columbia
- University of British Columbia
- Canada Research Chairs
- Canadian Institutes of Health Research
Zitieren
APA
Samra, S., Cook, E., Wilson, J., Sharma, M., Golding, L., Yao, D. T., Marsh, R. A., & Turvey, S. E. (2025). STAT6 gain-of-function disease: p.D519N is a new disease-causing variant that responds well to dupilumab treatment. Journal of Allergy and Clinical Immunology: Global, 4(3), 100494. https://doi.org/10.1016/j.jacig.2025.100494
Vancouver
Samra S, Cook E, Wilson J, Sharma M, Golding L, Yao DT, et al. STAT6 gain-of-function disease: p.D519N is a new disease-causing variant that responds well to dupilumab treatment. Journal of Allergy and Clinical Immunology: Global. 2025;4(3):100494. doi:10.1016/j.jacig.2025.100494
BibTeX
@article{Samra2025,
author = {Samra, Simran and Cook, Eleanor and Wilson, Jessica and Sharma, Mehul and Golding, Liam and Yao, David T and Marsh, Rebecca A and Turvey, Stuart E},
title = {STAT6 gain-of-function disease: p.D519N is a new disease-causing variant that responds well to dupilumab treatment},
journal = {Journal of Allergy and Clinical Immunology: Global},
year = {2025},
volume = {4},
number = {3},
pages = {100494},
doi = {10.1016/j.jacig.2025.100494}
}
EUVIMED